is9792 (7) - PowerPoint PPT Presentation

About This Presentation
Title:

is9792 (7)

Description:

Popular drugs preferred in seasonal affective disorder therapeutics include selective serotonin reuptake inhibitors (SSRIs), according to the report. While generics and branded drugs are widely available in seasonal affective disorder therapeutics market, Buproban and Citalopram continue to register relatively higher sales. FMI attributes this dominance to high availability of generic versions of the aforementioned drugs. – PowerPoint PPT presentation

Number of Views:19

less

Transcript and Presenter's Notes

Title: is9792 (7)


1
Seasonal Affective Disorder Therapeutics Market
is Pegged at Around US 450 Million in 2019
  • Feb 2020

Report Id REP-GB-8821 Published On
Feb-2019 Category Healthcare, Pharmaceuticals
Medical Devices
2
AboutFuture Market Insights
Future Market Insights (FMI) is a premier
provider of syndicated research reports, custom
research reports, and consulting services. We
deliver a complete packaged solution, which
combines current market intelligence, statistical
anecdotes, technology inputs, valuable growth
insights, aerial view of the competitive
framework, and future market trends. We provide
research services at a global as well as regional
level key regions include GCC, ASEAN,
and BRIC. Our offerings cover a broad spectrum of
industries including Chemicals, Materials,
Energy, Technology, Healthcare, and Retail. We
have a global presence with delivery centers
across India specializing in providing global
research reports and country research reports.
FMI is headquartered out of London, U.K., with a
state-of-the-art delivery center located in Pune,
India. We combine our knowledge and learning from
every corner of the world to distill it to one
thing the perfect solution for our client.
Research Capabilities
Sector Coverage
  • Customized Research
  • Syndicated Research
  • Investment Research
  • Social Media Research

  • Automotive and Transportation
  • Electronics, Semiconductor, and ICT
  • Retail and Consumer Products
  • Industrial Automation and Equipment
  • Chemicals Materials
  • Food and Beverages
  • Services and Utilities
  • Energy, Mining, Oil, and Gas

Subscription Information

For detailed subscription information please
contact Hari. T (Sr. Manager - Global Business
Development) T 44 (0) 20 7692 8790 D 44
20 3287 4268 Email hari.t_at_futuremarketinsights.co
m
3
Research Methodology (1/2)
  • Systematic Research Approach

In-depth secondary research is used to ascertain overall market size, top industry players, top products, industry associations, etc.
FMI formulates a detailed discussion guide to conduct expert and industry interviews
FMI develops a list of industry players (manufacturers), distributors, retailers and industry experts
FMI conducts interviews with industry experts, industry players, distributors and retailers
Data is validated by triangulation method, wherein secondary, primary and FMI analysis contribute to the final data
Data is scrutinized using MS-Excel to obtain qualitative and quantitative insights about the industry
FMI delivers industry insights and information in the required format (PDF)
  • Identifying key opinion leaders
  • Questionnaire design
  • In-depth interviews
  • Coverage across value chain
  • Key industry experts
  • Channel study
  • Developments
  • Market dynamics
  • Products
  • Conclusions

SOLUTION
  • Market participants
  • Key strengths
  • Product portfolio
  • Mapping as per value chain
  • Key focus segments

Primary Research
Secondary Research
Paid Publications
  • Linkedin
  • Zoominfo
  • Salesforce
  • Avention
  • Factiva
  • GBI
  • Genios
  • Meltwater
  • Company websites
  • Company annual reports
  • White papers
  • Financial reports

includes sources of databases
4
Seasonal Affective Disorder Therapeutics Market
Analysis
  • Seasonal Affective Disorder Therapeutics Market
    is Pegged at Around US 450 Million in 2019
  • The seasonal affective disorder (SAD)
    therapeutics market is pegged at around US 450
    million in 2019, with a modest Y-o-Y increase of
    3.9 over 2018, according to a recent
    intelligence report by Future Market Insights.
    While drugs and devices collectively contribute
    to the consumption volume of seasonal affective
    disorder therapeutics, the latter will remain a
    major shareholder in the market. Towards the end
    of 2019, more than 3.4 million devices are likely
    to be sold globally, in seasonal affective
    disorder therapeutics market.
  • Popular drugs preferred in seasonal affective
    disorder therapeutics include selective serotonin
    reuptake inhibitors (SSRIs), according to the
    report. While generics and branded drugs are
    widely available in seasonal affective disorder
    therapeutics market, Buproban and Citalopram
    continue to register relatively higher sales. FMI
    attributes this dominance to high availability of
    generic versions of the aforementioned drugs.
  • Bright light therapy that has been the most
    preferred line of treatment in seasonal affective
    disorder therapeutics continues to receive strong
    support from physicians and patients owing to
    positive end results. While more than half the
    sales of devices used in seasonal affective
    disorder therapeutics is accounted by light
    boxes, sales of desk lamps are also thriving at a
    brisk rate.
  • A highly recommended prophylactic measure
    involved in seasonal affective disorder
    therapeutics, light therapy is characterized by
    its rapid, reliable, and highly anti-depressant
    action. Extensive adoption of bright light
    therapy by the patients afflicted by a
    sub-syndromal disease and self-reporting patient
    population prompts at bolstered revenue
    visibility prospected for seasonal affective
    disorder treatment therapeutics in coming years.

5
Seasonal Affective Disorder Therapeutics Market
Analysis
  • Demand for Combination Therapy for SAD Picking Up
  • The report opines that light therapy is the first
    line of treatment that seasonal affective
    disorder therapeutics providers opt for. However,
    a possible ineffective outcome for certain
    patients of SAD related psychiatric illnesses and
    depression creates scope of combination
    therapies. Some of the recently reported clinical
    trials emphasize potential efficacy of
    combination of light therapy, psychotherapy, talk
    therapy, and antidepressants in seasonal
    affective disorder therapeutics.
  • Inaccessibility at workplaces or during traveling
    has been a shortfall of light box therapy over
    the years. To help patients suffering from SAD
    explore non-conventional alternatives to seasonal
    affective disorder therapeutics, Austria-based
    med-tech startup, Active Wearables, recently
    launched a wearable device Pocket Sky -
    providing light therapy, practically anywhere.
    The wearable has a wireless charging feature and
    the battery life is claimed to last for a couple
    of weeks. The Pocket Sky will potentially serve
    as a portable and lightweight light therapy
    solution to patients of seasonal affective
    disorder. Such innovations will continue to
    innovate the seasonal affective disorder
    therapeutics market landscape.
  • Inadequate availability of research data and
    ineffective documentation, especially related to
    use of bright light and blue light in light
    therapy, is posing a long-term challenge to rapid
    revenue growth of seasonal affective disorder
    therapeutics market. Moreover, proven adversities
    associated with excessive use of antidepressants
    also remain a concern among physicians and
    patients alike, limiting healthy growth prospects
    of seasonal affective disorder therapeutics
    market.

6
Seasonal Affective Disorder Therapeutics Market
Analysis
  • The report tracks performance of global seasonal
    affective therapeutics market over 2018-2028.
    In-depth strategic profiles of some of the
    leading players have been covered in the report,
    including Allergan plc, Eli Lily Company,
    GlaxoSmithKline plc, Pfizer Inc., Teva
    Pharmaceuticals Inc., F. Hoffmann-La Roche AG,
    Sanofi AG, Novartis AG, Janssen Pharmaceuticals,
    Inc., and Koninklijke Philips N.V. among others.
  • Sourcehttps//www.globenewswire.com/news-release/
    2019/02/18/1733703/0/en/Seasonal-Affective-Disorde
    r-Therapeutics-Market-is-Pegged-at-Around-US-450-M
    illion-in-2019-Future-Market-Insights.html
  • More from FMIs Healthcare, Pharmaceuticals and
    Medical devices Market Intelligence
  • Sleep Apnea Diagnostic System Market
  • Animal Artificial Insemination Market
  • About Us
  • Future Market Insights (FMI) is a leading market
    intelligence and consulting firm. We deliver
    syndicated research reports, custom research
    reports and consulting services which are
    personalized in nature. FMI delivers a complete
    packaged solution, which combines current market
    intelligence, statistical anecdotes, technology
    inputs, valuable growth insights and an aerial
    view of the competitive framework and future
    market trends.

7
Seasonal Affective Disorder Therapeutics Market
Analysis
  • Contact Us
  • Mr. Sudip SahaFuture Market Insights616
    Corporate Way, Suite 2-9018,Valley Cottage, NY
    10989,United StatesT 1-347-918-3531F
    1-845-579-5705T (UK) 44 (0) 20 7692 8790
    Sales sales_at_futuremarketinsights.comPress
    Office Press_at_futuremarketinsights.comFuture
    Market Insights

8
To know more about us, please visit our website
www.futuremarketinsights.com For sales queries
or new topics email us on sales_at_futuremarketinsi
ghts.com For media queries, contact the press
office at press_at_futuremarketinsights.com For
other queries contactHari. T (Sr. Manager -
Global Business Development) Future Market
Insights 3rd Floor,207 Regent Street, London
W1B 3HH T 44 20 7692 8790 D 44 20 3287
4268 Email hari.t_at_futuremarketinsights.com
Thank You
Future Market Insights Global Consulting
Private Limited (FMI)
Write a Comment
User Comments (0)
About PowerShow.com